Treatment-Resistant Depression | Ketamine/ Esketamine Program | Centerstone
cstnprapp11.centerstone.lan
Home / Depression / Ketamine/Esketamine Program for Treatment-Resistant Depression

Ketamine/Esketamine Program for Treatment-Resistant Depression

Centerstone has begun a new therapy program for individuals seeking treatment for severe depression at our Florida location.

About the Program

We are now certified to offer Spravato, a nasal spray that contains the FDA-approved medication Esketamine, and ketamine infusion therapy for people who have been treated for depression with no improvement in symptoms.

Both Spravato and ketamine infusion therapy are administered under the supervision of a medical professional, and patients are required to complete a comprehensive screening with a Centerstone physician prior to receiving treatment. Ketamine infusion therapy lasts approximately four hours for each dosage; Esketamine treatment takes approximately two hours.

Screenings and treatments are scheduled at our Bradenton, Fla., locations.

Patient Support

The Johnson & Johnson Patient Assistance Foundation Inc. (JJPAF) is an independent, nonprofit organization committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies. For more information, visit jjpaf.org.

Once Spravato has been prescribed, Janssen CarePath can help you find the resources you may need to help get started on the medication and stay on track. For more information, visit janssencarepath.com.

Frequently Asked Questions

What are Ketamine and Esketamine?

  • Ketamine is a medication traditionally used for anesthesia during surgery that was approved for use in the United States in 1970. While it does have a history as a drug of abuse, it is a safe and valuable medication when properly administered by a trained medical professional.
  • Esketamine was introduced as an anesthetic in Germany in 1997 and was then marketed in other countries. It is part of ketamine but differs slightly on a molecular level.

How long have they been used to treat depression?

  • For the past decade or so, researchers began studying the use of ketamine as an application for Treatment-Resistant Depression (TRD). Studies indicated that ketamine was highly successful at reducing symptoms of depression; some indicated relief of symptoms in about 80% of people prescribed. Despite their molecular differences, ketamine and Esketamine act essentially the same in their uses and effectiveness for treating TRD. Esketamine was approved by the U.S. Food and Drug Administration (FDA) in March 2019 under the drug name SpravatoTM.

When should Esketamine be considered for use?

  • Esketamine is approved to treat Treatment-Resistant Depression, which is diagnosed in patients who have suffered at least one major depressive episode and have experienced at least two failed drug therapies.

How is Esketamine used in treatment?

  • Spravato (Esketamine) is a fast-acting nasal spray approved for use in conjunction with an oral antidepressant in adults with Treatment-Resistant Depression.

How long does the treatment take?

  • For Esketamine administration, patients will need
    • 2 treatments per week for the first month (8 total)
    • 1 treatment per week for the second month (4 total)
    • 1 treatment every two weeks for the third month (2 total)
  • The initial visit will take about 2 hours; each subsequent appointment will take about 3 hours each.

Does insurance cover treatment costs?

  • Your insurance provider may cover Esketamine or Spravato. By enrolling in Janssen CarePath, you can receive guidance on submitting claims so that Spravato can be considered under your pharmacy benefits.

Do I need a referral before seeking treatment?

  • If you think Esketamine may be a good fit for you, it is a good idea to talk with your health care provider, but a referral by a medical professional is not required.

When can I expect to see results?

  • Patients typically begin to feel the effects within a few hours of treatment to the day after treatment. If the treatment schedule is adhered to, most patients will continue to feel the effects for up to several months.

For More Information

To learn more about the Spravato nasal spray, including answers to frequently asked questions, go online to spravato.com.

In the News

To see a report from WFLA-TV about this program, click here.

Call Today

For more information about Spravato self-pay rates, ketamine infusion therapy and Centerstone’s depression care services or to make an appointment, call (941) 782-4610.

Interested in Ketamine/Esketamine Program for Treatment-Resistant Depression?

If you are in crisis, please call our crisis lines, call 911 or visit the nearest emergency room.

New Clients

If you’d like to make a new appointment to see one of our therapists, please give us a call.

Current Clients

If you would like to reschedule an existing appointment, you can reach the clinic directly.

Send a message

Messages sent through this form are monitored during regular business hours (Monday – Friday, 9 a.m. – 5 p.m. Central Time). Messages received outside of these hours will be responded to the next business day.


Related Posts

No image set - Centerstone logo
Family Matters

Centerstone Awarded $2 Million from Administration for Children and Families

Centerstone was awarded a $1.9 million grant from the U.S. Department of Health and Human Services Children’s Bureau, an office of the Administration for Children and Families, to increase well-being, improve permanency, and enhance the safety of children who are in an out-of-home placement or are at risk of being place in an out-of-home case as a result of a parent’s or caretaker’s substance use. ...

No image set - Centerstone logo

Centerstone Receives $2 Million Grant to Continue Providing Comprehensive Community-Based Behavioral Health Services

Centerstone, a national leader in behavioral health care, recently announced it was awarded a $2 million grant extension from the Substance Abuse and Mental Health Services Administration (SAMHSA) to expand and improve community health care in Southern Illinois. The original grant was awarded in late 2018. “The grant will continue to improve access to community ...

No image set - Centerstone logo
Indiana

Centerstone Receives $175,000 Grant from Kendrick Foundation to Support School-Based Therapy in Indiana

Centerstone recently received a $175,000 philanthropic grant from The Kendrick Foundation in Morgan County, Ind., to support school-based therapy for students of Eminence Schools. The grant will also support life skills training. There were 10 grantees this year. The Foundation also awarded Centerstone funds for resource materials, staff/teacher training supplies, Dialectical Behavioral Therapy (DBT) training ...

No image set - Centerstone logo
Kentucky

PeerFit Helps Clients Improve Physical Health Along With Mental Health

May is Mental Health Month! This year’s theme from Mental Health America is Fitness #4Mind4Body. Centerstone Kentucky believes that fitness is important to good health and recovery, and tries to look at each person as a whole: mentally, physically, emotionally and spiritually. To that end, we offer a fitness center called PeerFit that offers all ...

No image set - Centerstone logo
Illinois

Centerstone Launches New Autism Service

Centerstone has launched Centerstone Autism Services: Think! Learn! Explore! (CASTLE), an intensive, evidence-based therapy program for children between the ages of two- and five-years-old who have been diagnosed with Autism Spectrum Disorder (ASD). CASTLE can help with a variety of challenges faced by children diagnosed with ASD including developing complex language and social skills (e.g., ...

Research Institute

American Addiction Centers’ Patient Outcome Findings

Utilizing three years of tracking and research with the assistance of Centerstone Research Institute, American Addiction Centers (AAC) is breaking new ground in addiction treatment with the release of its first patient outcome studies. Some key findings from the 12-month follow up substudy include: At 12 months, 63% of patients were abstinent from all substances. Days ...

Indiana

Members of Administration Visit Centerstone-partnered Program

Recently, Kellyanne Conway, U.S. Surgeon General Jerome Adams, Second Lady Karen Pence, and U.S. Department of Labor Secretary Alexander Acosta visited Belden Inc. in Richmond IN to learn about the “Pathways to Employment” program in which Centerstone partners with Belden. The program offers applicants that fail pre-employment drug screens an option for tailored rehabilitation, and the chance ...

Tennessee

Mandi Ryan Named in 2018 Nashville Medical News Women to Watch

Mandi Ryan, director of Healthcare Innovation, has been named among the 2018 Nashville Medical News Women to Watch. As administrative leader at Centerstone for Health Link – a state program to coordinate services for TennCare members with the highest behavioral health needs – Ryan has helped establish a health home for thousands of patients in Centerstone’s 21 ...

Illinois

Cathy Moehring to Retire from Centerstone

Centerstone announced that Cathy Moehring, Vice President of Quality Improvement for Centerstone, will retire at the end of 2018 after nearly 40 years of service. “Cathy has left her mark on the people she has served over the years, her team members and peers, along with our funders, and members of our board and the ...

Call Now